|
Hepatitis C, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
A total of 346 chronic hepatitis C (CHC) patients who finished the 48-week pegylated interferon-alpha and ribavirin (PEG IFN-α/RBV) treatment were enrolled in this study.
|
29654010 |
2018 |
|
Hepatitis C, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
The impact of chronic hepatitis C (CHC) on bone mineral density (BMD) has been well studied in adults with a relative paucity of data in children, especially concerning effect of treatment with pegylated interferon (PEG-IFN) plus ribavirin (RV).
|
28130750 |
2017 |
|
Hepatitis C, Chronic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Many studies have been published on the association between IFNL4 rs368234815 single-nucleotide polymorphism (SNP) and sustained virological response (SVR) in chronic hepatitis C (CHC) patients undergoing treatment with PEGylated interferon (PEG-IFN) plus ribavirin (RBV).
|
27180197 |
2016 |
|
Hepatitis C, Chronic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The best time point to determine cure of chronic hepatitis C was explored in a retrospective analysis of five published trials of sofosbuvir–ribavirin with or without PEG-IFN.
|
25421584 |
2015 |
|
Hepatitis C, Chronic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The single nucleotide polymorphism (SNP) ss469415590 in the interferon lambda-4 (IFNL4) gene has recently been reported to have an association with treatment response in chronic hepatitis C. However, any importance of the SNP in association with response to pegylated interferon (PEG-IFN) therapy in patients with chronic hepatitis B (CHB) is unclear.
|
26225703 |
2015 |
|
Hepatitis C, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
The introduction of pegylated interferon (PEG-IFN)-α in the treatment of chronic hepatitis C has led to an increase in sustained virological response.
|
25831972 |
2015 |
|
Hepatitis C, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although, the treatment of chronic hepatitis C (CHC) greatly improved with the use of direct antiviral agents, pegylated-interferon (PEG-IFN) plus ribavirin remains an option for many patients, worldwide.
|
25844942 |
2015 |
|
Hepatitis C, Chronic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The IL28B genotype in rs12979860 predicts success of peginterferon/ribavirin (PEG/RBV) therapy in patients with chronic hepatitis C (CHC).
|
24205831 |
2014 |
|
Hepatitis C, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ribavirin improves treatment response to pegylated-interferon (PEG-IFN) in chronic hepatitis C but the mechanism remains controversial.
|
23396509 |
2014 |
|
Hepatitis C, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study aimed to examine the therapeutic effect and prognostic indicators of pegylated interferon (PEG-IFN) and ribavirin (RBV) combination therapy in thrombocytopenic patients with chronic hepatitis C, hepatitis C virus (HCV)-related cirrhosis, and those who underwent splenectomy or partial splenic embolization (PSE).
|
24065124 |
2014 |
|
Hepatitis C, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
The occurrence of anti-IFN antibodies is associated with non-response to PEG-IFN in chronic hepatitis C. This study investigated the association between anti-IFN antibodies and response to PEG-IFN in CHB.
|
24296674 |
2014 |
|
Hepatitis C, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hepatitis C virus genotypes circulating in patients with chronic hepatitis C in Thailand and their responses to combined PEG-IFN and RBV therapy.
|
24777626 |
2014 |
|
Hepatitis C, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
A strong association between single nucleotide polymorphisms (SNPs) of IL28B and treatment outcomes of pegylated interferon-α (PEG IFNα) and ribavirin (RBV) has been shown in chronic hepatitis C (CHC) patients with genotype 1.
|
24102823 |
2014 |
|
Hepatitis C, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Randomized clinical trials and non-randomized clinical studies comparing PEG-IFN-α2a with PEG-IFN-α2b in association with ribavirin in adult patients with chronic hepatitis C were included.
|
23436591 |
2013 |
|
Hepatitis C, Chronic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Chronic hepatitis C (CHC) patients achieving rapid virological response (RVR) on PEG-IFN/ribavirin (P/R) therapy have high chance of sustained virological response (SVR).
|
23874444 |
2013 |
|
Hepatitis C, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although the anti-hepatitis C virus (HCV) effect of statins in vitro and clinical efficacy of fluvastatin combined with Pegylated interferon (PEG-IFN)/ribavirin therapy for chronic hepatitis C (CHC) have been reported, the details of clinical presentation are largely unknown.
|
22989264 |
2013 |
|
Hepatitis C, Chronic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The purpose of this study was to investigate the relationship between methylation of SOCS-1 and sustained virologic response (SVR) in chronic hepatitis C (CHC) patients treated with pegylated interferon (PEG-IFN)-alpha and ribavirin (RBV).
|
23702664 |
2013 |
|
Hepatitis C, Chronic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We intended to compare the efficacy and safety of PEG-IFN alfa-2a with those of PEG-IFN alfa-2b in Korean patients with chronic hepatitis C virus (HCV).
|
23627926 |
2013 |
|
Hepatitis C, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therapy of chronic hepatitis C with PEG-IFN α-2b plus ribavirin in patients with genotype 2 or 3: 16 versus 24 weeks, clinical outcome and direct cost analyses.
|
23743559 |
2013 |
|
Hepatitis C, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
To evaluate the efficacy and safety of telaprevir in combination with peginterferon-α2b (PEG-IFN) and ribavirin (RBV) in patients with chronic hepatitis C.
|
21827730 |
2012 |
|
Hepatitis C, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
A total of 187 patients with chronic hepatitis C received PEG IFN-α/ribavirin or natural IFN-β/ribavirin therapy.
|
22554247 |
2012 |
|
Hepatitis C, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Genotype 1 (G1) chronic hepatitis C (CHC) patients achieving a rapid virological response (RVR) on pegylated interferon (PEG-IFN) plus ribavirin have a high chance of sustained virological response (SVR), influenced by IL28B status, viral load, fibrosis and insulin resistance.
|
22505587 |
2012 |
|
Hepatitis C, Chronic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Treatment of genotype 1 naïve chronic hepatitis C with PEG-IFN and ribavirin (RBV) for 48 weeks results in SVR in approximately 40% of patients.
|
23199504 |
2012 |
|
Hepatitis C, Chronic
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pegylated interferon (PEG-IFN) α-2b and ribavirin (RBV) treatment of chronic hepatitis C virus (HCV) infection is associated with a substantially elevated risk of discontinuation.
|
22098185 |
2012 |
|
Hepatitis C, Chronic
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The standard treatment for patients with chronic hepatitis C (CHC), pegylated interferon-α (PEG-IFN) plus ribavirin (RBV) does not provide a sustained virological response (SVR) in all patients.
|
22713131 |
2012 |